Associated Papers
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C et al.
European Journal of Haematology, 2023
Nuclear PTEN's Functions in Suppressing Tumorigenesis: Implications for Rare Cancers.
Langdon CG
Biomolecules, 2023
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
35906470 (PubMed )
Supplement: 41598_2022_17271_MOESM2_ESM.pdf
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
Awidi A et al.
Genetic Testing and Molecular Biomarkers, 2012
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Soverini S et al.
Blood, 2011
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T et al.
Haematologica, 2009
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T et al.
Haematologica, 2008
The Nuclear Face of PTEN: Implications in Cancer Prognosis and Targeted Therapy.
Ghosh MK et al.
Biofactors (oxford, England), 0
Select a paper to view details